bluuebunny/crossref_metadata_2025_split huggingface dataset:
Hematoma of liver: A lesion‐mimicking hepatic neoplasm
Authors: Jochimsen P. R. , Platz C. E. , Pearlman N. W. 
Published: February 2007

AbstractA plethora of case reports of women on birth control agents who present with hepatic masses and who are ultimately found to have liver neoplasms have overshadowed the clinicians' awareness of other possible diagnoses in patients who present in a similar fashion. Hematomas of the liver, secondary to vascular lesions induced by these agents, must be considered and preoperative attempts to make the diagnosis must be ensured by obtaining appropriate studies.
Serum fucose as a monitor for recurrent malignancy
Authors: Wallack Marc K. , Brown Arthur S. , Rosato Ernest F. , Rubin Stephen , Johnson Joan L. , Rosato Francis E. 
Published: February 2007

AbstractSerum fucose determinations were performed on 19 patients with “stable” or “inactive” malignancies, 33 patients with “active” malignancies, and 14 “normals.” A significant difference in the values between “normal” and “stable” patients and those with “active” cancer is shown. A role for this relatively simple serological test for diagnosing and following metastatic cancer is suggested.
The effect of mixed distributions on the methods of survival analysis
Authors: Bross Dean S. 
Published: February 2007

AbstractA study of the effectiveness of preoperative radiation as an adjuvant for surgery for patients with invasive bladder carcinoma revealed a subpopulation of patients having advanced disease who could not benefit from radiation treatment. The effect of such a group of patients on the efficiency of 2 common nonparametric tests is investigated here. Both Gehan's tests and Greenwood's tests were shown to have a very low efficiency when compared with a parametric test when this group of patients is present.
Antitumor tests of amygdalin in spontaneous animal tumor systems
Authors: Stock C. Chester , Martin Daniel S. , Sugiura Kanematsu , Fugmann Ruth A. , Mountain Isabel M. , Stockert Elisabeth , Schmid Franz A. , Tarnowski George S. 
Published: February 2007

AbstractIn a series of 6 experiments with CD8F1 mice with spontaneous mammary adenocarcinomas Sugiura noted by macrovisual observation with some histology an overall average of 21% of mice with lung metastases when treated with 1,000–2,000 mg/kg/day of amygdalin compared with 90% of the control mice. The significance attributed to those early observations is seriously challenged by the negative findings of 3 independent investigators, by 2 out of 3 negative cooperative experiments in which Sugiura participated, and particularly by the blind experiment in which he and others under blind readings found no anticancer activity.Treatment of Swiss albino mice showed no destructive effect upon their spontaneous mammary adenocarcinomas. Of the treated mice, 22% were found by macrovisual observation to have lung metastases while 91% were noted among the controls. The results are subject to questions raised in the discussion.Amygdalin at 2,000 mg/kg/day was ineffective both in treating and preventing the development of spontaneous leukemia in AKR mice. At 1,000 mg/kg/day it was not found effective in preventing or significantly delaying the development of spontaneous mammary tumors in CD8F1 mice.In summary, we do not have evidence to support taking amygdalin to clinical trial, although other considerations may require that one be conducted.
Long‐term survival with thorotrast cervical granuloma
Authors: Lung Richard J. , Harding Robert L. , Herceg Stephen J. , Schantz John C. , Miller Stephen H. 
Published: February 2007

AbstractThorium dioxide, a radioactive contrast material, was commonly used for cerebral angiography prior to recognition of its radiation hazard. Extravasation of the material into the extravascular tissue in the neck results in granuloma formation, thorotrastoma, long‐term morbidity, and an increased incidence of benign and malignant tumors.We report our experience with the management of 2 patients who underwent cerebral angiography with thorotrast more than 25 years ago. Aggressive surgical excision of involved tissue is warranted to ameliorate symptoms and diminish the risk of malignancy.
Malacoplakia of a cadaveric renal allograft: A case report
Authors: Mullan H. , Hesse V. E. 
Published: February 2007

AbstractA case of malacoplakia in a cadaveric renal allograft is presented. Infection and immunotherapy are presented as possible etiologic factors. The pathogenesis of malacoplakia is discussed with reference to histologic findings in this specific case. The suggestion is made that an altered macrophage response in this disease is the reason for this granulomatous lesion of the bladder.
Primary malignant melanoma of the small intestine and the APUD cell concept
Authors: Krausz Michael M. , Ariel Ilana , Behar Albert J. 
Published: February 2007

AbstractA primary melanoma of the small intestine is reported. A possible explanation of its origin according to the APUD cell concept is suggested. This concept may lessen the doubts and confusion whenever an intestinal melanoma is discovered and a primary tumor at one of the more common sites can reasonably be excluded.
“Localized” carcinoma of the mobile tongue and floor of the mouth—a lesion frequently misjudged and undertreated
Authors: McColl Harry A. , Horwood Jonathan 
Published: February 2007

AbstractA retrospective study of 74 cases of cancer of the mobile tongue and floor of the mouth, diagnosed between 1949 and 1975, with a two‐year minimum follow‐up was undertaken. The lesions were TNM staged, stages I and II accounting for 56 cases (76%) and stages III and IV accounting for 18 cases (24%). The analysis was restricted to the “localized” stage I and stage II lesions. In this group failure occurred in 31 patients, or 55% of the group. Failure at the primary site accounted for 10 of the failures, failure at both primary and cervical lymph nodes accounted for 14, and failure at cervical lymph nodes only accounted for 7 of the failures. The treatment for these “localized” lesions was then analyzed for modality, adequacy, presence or absence of planning failure, and survival. The results indicate the lethal nature of this lesion when inadequately treated and strongly suggest more extensive use of prophylactic therapy to the cervical lymph nodes.
Management of malignant pleural effusion
Authors: Greenwald David W. , Phillips Clay , Bennett John M. 
Published: February 2007

AbstractA pleural effusion is a frequent complication of malignant disease. Essential to the care of oncology patients is a fundamental knowledge of the pathophysiology and treatment of such effusions. This article discusses the current thoughts concerning the occurrence of malignant effusions, outlines the current available methods and agents employed for control, and presents a modification of the thoracostomy procedure that appears to be more effective than the standard procedure.
Adriamycin, bleomycin, and CCNU as effective induction chemotherapeutic agents in advanced squamous cell carcinoma (COG protocol 7333)
Authors: Scarborough James P. , Metter Gerald E. , Moseley H. Stephens , Kraybill William G. , Davenport Charlene , Strawitz Joseph G. , Cobau Charles D. , Golomb Frederick M. , Fletcher William S. 
Published: February 2007

AbstractTwenty‐six member institutions of the Central Oncology Group entered 154 patients in this two‐armed, phase III study comparing the effects of adriamycin, bleomycin, and CCNU against a variety of squamous cell carcinomas. The combination of adriamycin and bleomycin produced a 43% overall response rate in primary tumors of the head and neck, which included two complete responses. This compares favorably to the results obtained with methotrexate and other agents previously reported. The combination of adriamycin and bleomycin will probably be the most useful for induction chemotherapy because both drugs have cumulative toxicities and the duration of response to this combination is short.
Gastric carcinoma survival at the pennsylvania hospital — 1964 to 1974
Authors: Lerner Harvey J. , Gindes Daniel 
Published: February 2007

AbstractDespite major improvements in diagnosis, anesthesia, surgical techniques, and postoperative care, the survival rate for adenocarcinoma of the stomach remains a dismal one. In our series of 109 patients, almost all patients seen were diagnosed too late to effect any kind of surgical care.In the period from January 1964, to December 1974, 122 patients were admitted to Pennsylvania Hospital with a diagnosis of gastric adenocarcinoma. Of the 109 patients followed to their death, only seven survived 5 years; the longest survival was 80 months.Among the 33 patients not resected, median survival was only one month. Of the 74 patients who had surgical resections survival ranged from a median of 5.5 months for those who had total gastrectomy to a median of 8 months for those receiving subtotal gastrectomy.
Small cell undifferentiated bronchogenic carcinoma: Current status with emphasis upon the role of chemotherapy
Authors: Johnson Paul S. , Foley John F. , Kessinger Anne , Lemon Henry M. 
Published: February 2007

AbstractCurrent opinions concerning tumor biology and clinical characteristics of small cell undifferentiated bronchogenic carcinoma are reviewed. Special emphasis is placed upon chemotherapy for this lung cancer subtype and presently achievable response rates and survival times are presented. A series of 16 patients with small cell undifferentiated bronchogenic carcinoma is also presented. All patients were given cyclophosphamide, methotrexate, vincristine, and procarbazine as treatment for this neoplasm. Sixty‐eight percent of patients responded and the survival time in partial responders was 33.4+ weeks as compared to 13.7 weeks with nonresponders. These data correlate well with the previous data of Alberto et al [Alberto P, Brunner KW, Martz G, Obrect JP: Cancer 38:2208–2216, 1976], who investigated the same agents for this tumor, but at higher dosages.
Immunotherapeutic effect of tumor necrosis after cryosurgery, electrocoagulation, and ligation
Authors: Bryan Iii H. Neel , Ritts Roy E. 
Published: February 2007

AbstractTumor necrosis in situ by cryosurgery, electrocoagulation, or ligation generally induces or augments some increase in tumor‐specific transplantation immunity (TSTI) as compared with excision. Excision of the tumor 24 hours after it has been rendered ischemic by either ligation or cryosurgery seems to produce TSTI that is significantly greater than that after excision of viable tumor without prior ligation or cryosurgery; the degree of this immunity is similar to that seen after the tumor is left in situ indefinitely after treatment. These data suggest that most of the immunization following tumor necrosis in situ occurs within 24 hours of treatment. The experimental findings support the clinical reports of putative immunologic potentiation after tumor necrosis in situ.
Human carcinoma‐associated precursor antigens of the NM blood group system
Authors: Springer G. F. , Desai P. R. , Murthy M. S. , Scanlon E. F. 
Published: February 2007

AbstractBlood group NM specificities occur in healthy, benign and carcinomatous breast glands and those of the gastrointestinal (G.I.) tract, but the precursors in their biosynthesis, T (Thomsen‐Friedenreich) and Tn, are found in adenocarcinomata and not in benign or healthy tissues. T‐and Tn‐antigenic specificities are thus human carcinoma‐associated. All humans possess anti‐T and anti‐Tn antibodies. Patients with breast or G.I. tract carcinoma show statistically significant alteration of anti‐T titer levels when compared to patients with benign disease and to healthy controls. Breast carcinoma patients but not healthy people showed cellular immunity to T antigen in vitro and in vivo. Most striking was the delayed‐type hypersensitivity reaction, which was positive in over 90% of ductal breast carcinoma patients tested and negative in all presumably healthy individuals. T antigen is readily prepared from healthy human red blood cells in uncontaminated form, and free of HL‐A and Au antigens. T antigen and anti‐T antibodies may be useful in combating some human adenocarcinomata.
Malignant mesothelioma presenting in the pleura and peritoneum
Authors: Mischler Nicholas E. , Chuprevich Thomas , Johnson Robert O. , Tormey Douglass C. 
Published: February 2007

AbstractMalignant mesothelioma presenting in the pleura and peritoneum is described in a middle‐aged man. The patient lacked significant asbestos exposure which is not unexpected from both the clinical literature and animal inhalation tumor data. Computerized axial tomographic correlation is provided. Partial remission was achieved with the administration of adriamycin and DTIC.
Achalasia of the esophagus associated with Hodgkin disease
Authors: Peeples William J. , El‐Mahdi Anas M. , Rosato Francis E. 
Published: February 2007

AbstractEsophageal achalasia has not been reported in the literature as a complication of Hodgkin disease. Involvement of the esophagus is rare but when present, consists mostly of bleeding, ulceration or diverticuli. A case is reported in a fifty‐one year old female with achalasia of the distal third of the esophagus associated with Hodgkin disease, Stage II B.
Five‐day continuous infusion of 5‐fluorouracil for advanced colorectal, gastric, and pancreatic adenocarcinoma
Authors: Hartman Herbert A. , Kessinger Anne , Lemon Henry M. , Foley John F. 
Published: February 2007

AbstractIn a retrospective study, 58 patients with advanced colorectal carcinoma received one or more 5‐day infusions of 5‐FU at 20 mg/kg per 24 hours followed by weekly IV 5‐FU at 15 mg/kg. In 36 patients who received the infusion as first treatment (Group A), the response rate was 23% with a median duration of response of 8.0 months. No improvement in survival was noted. In 22 patients treated with the infusion after relapse on weekly 5‐FU (Group B), the response rate was 10.5% with a median duration of response of 4.5 months. Stable disease for 3‐6 months was seen in 21%. Survival in Group B was improved when compared with a similar group of patients treated by weekly 5‐FU without infusion (Group CB), but statistical significance was not obtained. Twenty percent of patients were alive two years after relapsing on weekly 5‐FU when given the five‐day infusion of 5‐FU and re‐initiated on weekly 5‐FU.Toxicity t o the five‐day infusion of 5‐FU was minimal. Three of 69 (4.3%) infusions were not completed because of toxicity.A separate review of procarbazine indicated that it was minimally active in colorectal carcinoma.Other patients with gastric and pancreatic carcinoma were reviewed but no statistical significance for 5‐FU infusion was seen for survival.A five day continuous infusion of 5‐FU is recommended for colorectal cancer patients who relapse on weekly 5‐FU therapy. Further study of the infusion in combination with other chemotherapy is warranted.
Increased incidence of breast carcinoma in patients with irradiation for post‐partum mastitis: A screening situation
Authors: Logan Wende Westinghouse , Mansur Paula S. , Cullinan Angeline , Kowaluk Eugene , Hutchings Joan , Hempleman Louis H. 
Published: February 2007

AbstractIn Rochester, New York, 606 women were treated with ionizing radiation for post‐partum mastitis, mostly between 1940 and 1955. Two‐thirds of all breasts were treated, the average dose per breast being 377 rads (at 2.5 cm breast depth). Mammographic examinations were performed on 265 of these women still residing in this vicinity. Two nonpalpable carcinomas (with no axillary node metastases) were found in the twelve breast lesions that have been biopsied. Some of the biopsies revealed premalignant changes. It is recommended that women in this high‐risk category have close medical supervision, as well as periodic mammographic evaluation, and that the importance of periodic breast self‐examinations should be emphasized.
Suppressor cells in the pelvic lymph nodes regional to bladder cancer
Authors: Herr Harry W. 
Published: February 2007

AbstractRegional lymph node cells from some patients with locally advanced bladder carcinoma were found to inhibit the reactivity of normal and autologous peripheral blood lymphocytes in mixed leukocyte culture. The data suggest that suppressor cells are generated in draining lymph nodes of these patients by a high concentration of tumor‐derived products and may have suppressive influence on host immunologic defense mechanisms.
Combination chemotherapy for soft‐tissue sarcomas: A phase III study
Authors: Cruz A. B. , Thames E. A. , Aust J. B. , Metter G. , Ramirez G. , Fletcher W. S. , Altman S. J. , Frelick R. W. , Hill G. J. 
Published: February 2007

AbstractA total of 144 patients with advanced sarcomas were entered into a randomized prospective protocol with four treatment arms utilizing different combinations of chemotherapeutic agents. Of these, 120 patients (83%) were judged acceptable. Treatment #1: actinomycin‐D (Act‐D), 0.01 mg/kg IV, days 1‐5; phenylalanine mustard (L‐PAM), 4 mg PO, days 1‐10 every six weeks. Treatment #2: Act‐D, 0.01 mg/kg IV, days 1‐5; L‐PAM, 4 mg PO, days 1‐10;vincristine, 1 mg IV, days 1,8,15,22,29,36, repeat every six weeks. Treatment #3: Act‐D, 0.01 mg/kg IV, days 1‐5; L‐PAM, 4 mg PO, days 1‐10; NSC‐1026,200 mg/kg IV, days 1‐6. Treatment #4: Adriamycin, 0.4 mg/kg IV, days 1,2,3,8,9,10, then 2XWK starting day 15 (max. 1,200 mg). There was a provision that upon progression of the disease in the first three treatment regimens, patients would be crossed over to Treatment #4. Responses were as follows: #1 ‐ Partial Response (PR) 1/25; No Change (NC) 9/25 (36%). #2 ‐ NC 17/26 (65%). #3 ‐ NC 13/25 (52%). #4 ‐ Complete Response (CR) 1/41; PR 6/41; (15%); NC 27/41 (66%). Clearly Treatment #4 was the best arm, with a 17% response rate and an initial progression rate of 17%. The only other response was a partial in #l. The difference is statistically significant (H = 17.247, P = 0.0006). If the responders to Adriamycin were analyzed without crossovers, the response rate would be 22% (6/27). (H = 14.079, P = 0.003). Median times to progression were 12.5,8.7 weeks for #1 and #2, and 5 weeks for #3 and #4. There was no significant difference in the median survival times among the four treatment arms. It appears that Adriamycin as a single drug is superior to the drug combinations and would probably be even more effective used in combination with known active agents.
Combined chemoimmunotherapy and radiation therapy of inflammatory breast carcinoma
Authors: Krutchik Allan N. , Buzdar Aman U. , Blumenschein George R. , Hortobagyi Gabriel N. , Tashima Charles K. , Gutterman Jordan U. , Yap H. Y. , Hersh Evan M. 
Published: February 2007

AbstractThirty‐two patients with a diagnosis of primary inflammatory breast carcinoma were treated with combination chemoimmunotherapy consisting of 5‐fluorouracil, doxorubicin hydrochloride (Adria‐mycin), and cyclophosphamide (FAC) plus BCG followed by radiation therapy. This group of patients was compared to a group of 32 consecutive historical controls treated with radiation therapy alone. The estimated mean disease‐free interval for the FAC‐BCG group was 16 months, compared to 9 months for the radiation therapy alone group (P <0.01). The estimated median survival for the FAC‐ BCG treated group was 24 months, compared to 18 months for the radiation therapy alone group (P = 0.03). The combined modality approach consisting of chemoimmunotherapy and radiation therapy significantly improved the disease‐free interval and survival of patients with inflammatory breast carcinoma.
Comparison of intramural 5‐fluorouracil and more conventional routes of drug administration on concentrations in gastric regional lymph nodes: A potential for trans‐endoscopic adjuvant chemotherapy
Authors: Yamada Kazuki , Murphy Gerald P. , Douglass Harold O. 
Published: February 2007

AbstractIntramural injection of 20 μCi (2‐14C) 5‐fluorouracil(5‐FU) into the gastric submucosa of dogs and baboons was employed to evaluate the kinetics of 5‐FU distribution following this route of administration and to compare these results with those following intraluminal, intravenous, and local intra‐ arterial injections. Measurements of radioactivity taken over a six‐hour period after injections demonstrated that the greatest concentration of isotope in samples of gastric wall and perigastric lymph nodes was found after administration of the drug directly into the stomach wall. Clinical application of intramural injections of 5‐FU into the stomach wall under direct gastroscopic visual control, may be worthy of trial in patients with gastric cancer.
Lymphocytes subpopulation in normal family members of patients with alpha‐chain disease
Authors: Alsabti ELIAS A. K. , Safo M. H. , Shaheen A. 
Published: February 2007

AbstractNormal family members of eight diagnosed patients suffering from alpha‐chain disease had been investigated by immunoelectrophoresis for abnormal alpha‐chain protein in their serum. The pattern was demonstrated in four families only, of different members, but all are of the first‐degree relationship. The aim of the study was to determine any possible hereditary defect of the immune system in such patients, as compared to the immune system of the normal members of the family who had abnormal protein in their serum. It was found that in both patients and normal members, the proportion of circulating B‐lymphocytes was much higher than normal, whereas that of T‐lymphocytes was lower than normal. Neither could be sensitized to DNCB, and their skin tests to tuberculin were negative. From all these findings, it was concluded that the disease was a B‐cell disease of IgA type transmitted by a hereditary factor associated with a low level of cellular immunity. Further studies are required to support this hypothesis.
Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED)
Authors: Buzdar Aman U. , Blumenschein George R. , Smith Terry L. , Tashima Charles K. , Hortobagyi Gabriel N. , Yap H. Yong , Gutterman Jordan U. , Hersh Evan M. , Gehan Edmund A. 
Published: February 2007

AbstractA combination of 5‐fluorouracil, Adriamycin, cyclophosphamide, and BCG (FAC‐BCG) was evaluated as adjuvant treatment in breast cancer patients following surgical excision and/or radiation of first site of recurrent disease.In a group of 68 patients treated with FAC‐BCG, the estimated proportion remaining free of disease at 2 years from first recurrence was 69%, compared to 24% in 60 historical control patients (P < 0.01).Estimated 2‐year survival rate from first recurrence was 85% for the FAC‐BCG patients and 78% for the controls (P = 0.07). This regimen has significantly prolonged the disease‐free interval from the first recurrence, but additional follow‐up is needed to determine its effect on long‐term survival.